Sativex Publications

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

SATIVEX Clinical Manuscripts with GW Author(s)

CANCER

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer Related Pain
Jeremy R Johnson MB, ChB, Mary Burnell-Nugent MB, BChir, Dominique Lossignol M, ChB, MRCG, DRCOG, E Doina Ganae-Motan MD, Richard Potts BSc (Hons) MICR, Marie T Fallon MB, ChB, MD, FRCP (E), FRCP (Glasg)
J Pain Symptom Manage 2010;39:167-79

Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial
Russell K. Portenoy,* Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, Lauren Shaiova, Sharon Weinstein, Robert McQuade, Stephen Wright,and Marie T. FallonThe Journal of Pain, Vol 13, No 5 (May), 2012: pp 438-449

A Multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis
Vachová M, Novotná  A, Mares J, Taláb R, Fiedler J, Lauder H, Taylor L, Etges T, Wright S, Nováková IJ.
Mult. Scler. (2014); 1(2): 1000122

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
W Notcutt, R Langford, P Davies, S Ratcliffe and R Potts
Mult Scler 2012 18: 219

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
Derick T Wade, Christine Collin, Colin Stott and Paul Duncombe 
Multiple Sclerosis 2010 16(6) 707–714

MULTIPLE SCLEROSIS - BLADDER DYSFUNCTION

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
RBC Kavia, D De Ridder, CS Constantinescu, CG Stott and CJ Fowler
Mult Scler. 2010 Nov;16(11):1349-59. doi: 10.1177/1352458510378020. Epub 2010 Sep

NEUROPATHIC PAIN

A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
B. Hoggart, S. Ratcliffe, E. Ehler, K.H. Simpson, J. Hovorka, J. Lejcko, L. Taylor, H. Lauder, M Serpell
J Neurol 2015 Jan; 262(1): 27-40

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E
Eur J Pain 2014 Jan 13. doi: 10.1002/j.1532-2149.2013.00445.x. [Epub ahead of print]

PHASE 1

A Multiple-Dose, Randomized, Double-Blind, Placebo- and Active-Controlled, Four-Arm, Parallel Group Thorough QT/QTc Study to Evaluate the Electrophysiologic Effects of Sativex
Edward M. Sellers, Kerri Schoedel, Cindy Bartlett, Myroslava Romach, Ethan B. Russo, Colin G. Stott, Stephen Wright, Linda White,Paul Duncombe, and Chien‐Feng Chen
Clin Pharmacol Drug Develop, in press 2013

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
Colin Stott, Linda White, Stephen Wright, Darren Wilbraham and Geoffrey Guy
SpringerPlus Online, 2013; 2:236, 1-15

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray
C. G. Stott, L. White, S. Wright, D. Wilbraham & G. W. Guy
Eur J Clin Pharmacol, 2013;69 (4),825-834.

A phase I study to assess the single and multiple dose pharmacokinetics of THC:CBD oromucosal spray
C. G. Stott, L. White, S. Wright, D. Wilbraham & G. W. Guy
Eur J Clin Pharmacol, 2013; 69(5),1135-1147

A randomized, doubleblind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use
Kerri Alexandra Schoedel, Nancy Chen, Annie Hilliard, Linda White, Colin Stott, Ethan Russo, Stephen Wright, Geoffrey Guy, Myroslava K. Romach and Edward M. Sellers
Hum. Psychopharmacol Clin Exp 2011; 26: 224–236

OTHER SATIVEX/CANNABINOIDS

A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK
Potter DJ
Drug Test Analysis 2013 Sep 30. doi: 10.1002/dta.1531. [Epub ahead of print]

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex) in people with multiple sclerosis: a new approach
Stephen Wright, Paul Duncombe and Douglas G Altman
Trials (2012), 13: 189

Abuse potential and psychoactive effects of d-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine
Philip Robson
Expert Opin. Drug Saf. (2011) 10(5):675-685

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
Ethan B Russo
British Journal of Pharmacology (2011) 163 1344–1364

Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex, a Cannabis-Based Medicine
Ethan B. Russo, Geoffrey W. Guy, and Philip J. Robson
Chem Biodivers. 2007 Aug;4(8):1729-43.

Cannabinoid- Based Medicines for Neurological Disorders - Clinical Evidence
Stephen Wright
Mol Neurobiol (2007) 36:129-136

A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
Ethan Russo, Geoffrey W Guy
Medical Hypotheses (2006) 66, 234-246

Cannabinoids for the pharmaceutical industry
Colin G Stott & Geoffrey W Guy
Euphytica 140: 83-93, 2004

Cannabis and Cannabis Based Medicine Extracts: Additional Results
Ethan Russo
Journal of Cannabis Therapeutics 2003; 3(4): 153-161

NOTE:

Sativex is not approved for use in the United States.  The publications provided on this website are for your information and interest only and comprise publications authored by GW Pharmaceuticals. They are not intended to be comprehensive, and they do not constitute and must not be relied on as medical or other professional advice.

Each article cited is the property of its respective publisher.